Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

261. Ablation Procedures for Rhythm Control in Patients With Atrial Fibrillation: Clinical and Cost-Effectiveness Analyses

Ablation Procedures for Rhythm Control in Patients With Atrial Fibrillation: Clinical and Cost-Effectiveness Analyses Ablation Procedures for Rhythm Control in Patients With Atrial Fibrillation: Clinical and Cost-Effectiveness Analyses | CADTH.ca Find the information you need Ablation Procedures for Rhythm Control in Patients With Atrial Fibrillation: Clinical and Cost-Effectiveness Analyses Ablation Procedures for Rhythm Control in Patients With Atrial Fibrillation: Clinical and Cost (...) -Effectiveness Analyses Published on: September 17, 2010 Product Line: Result type: Report Atrial fibrillation (AF) is a type of heart rhythm disturbance or arrhythmia that affects over 200,000 Canadians, including more than 5% of the population over the age of 65. The most common type of arrhythmia, AF is associated with a high degree of morbidity and mortality, including an increased risk of stroke. First-line therapy for AF is antiarrhythmic drugs (AADs), which are used to either terminate the arrhythmia

CADTH - Health Technology Assessment2015

262. Surgical Ablation for Atrial Fibrillation.

Surgical Ablation for Atrial Fibrillation. Surgical Ablation for Atrial Fibrillation. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26222570 Format MeSH and Other Data E-mail Subject Additional text E-mail (...) Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Jul 30;373(5):484. doi: 10.1056/NEJMc1506893. Surgical Ablation for Atrial Fibrillation. , , . Comment on [N Engl J Med. 2015] [N Engl J Med. 2015] [N Engl J Med. 2015] PMID: 26222570 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Grant support Full Text Sources Medical PubMed Commons 0 comments How to cite

NEJM2015

263. Surgical Ablation for Atrial Fibrillation.

Surgical Ablation for Atrial Fibrillation. Surgical Ablation for Atrial Fibrillation. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26222571 Format MeSH and Other Data E-mail Subject Additional text E-mail (...) Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Jul 30;373(5):483. doi: 10.1056/NEJMc1506893#SA1. Surgical Ablation for Atrial Fibrillation. . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26222571 DOI: [Indexed for MEDLINE] Publication types MeSH terms Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text

NEJM2015 Full Text: Link to full Text with Trip Pro

264. Surgical Ablation for Atrial Fibrillation.

Surgical Ablation for Atrial Fibrillation. Surgical Ablation for Atrial Fibrillation. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26222572 Format MeSH and Other Data E-mail Subject Additional text E-mail (...) Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Jul 30;373(5):483. doi: 10.1056/NEJMc1506893#SA2. Surgical Ablation for Atrial Fibrillation. , , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26222572 DOI: [Indexed for MEDLINE] Publication types MeSH terms Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text

NEJM2015 Full Text: Link to full Text with Trip Pro

265. Ablation Procedures for Rhythm Control in Patients With Atrial Fibrillation: Clinical and Cost-Effectiveness Analyses

Ablation Procedures for Rhythm Control in Patients With Atrial Fibrillation: Clinical and Cost-Effectiveness Analyses Ablation Procedures for Rhythm Control in Patients with Atrial Fibrillation: Clinical and Cost-Effectiveness Analyses | CADTH.ca Find the information you need Ablation Procedures for Rhythm Control in Patients with Atrial Fibrillation: Clinical and Cost-Effectiveness Analyses Ablation Procedures for Rhythm Control in Patients with Atrial Fibrillation: Clinical and Cost (...) -Effectiveness Analyses Published on: August 12, 2012 Product Line: , CADTH Technology Overviews Issue: Volume 2, Issue 1 Result type: Report Adapted from Assasi N, Blackhouse G, Xie F, Gaebel K, Robertson D, Hopkins R, Healey J, Roy D, Goeree R. [Technology Report, No. 128]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010. For more information on this project, visit Introduction Atrial fibrillation (AF), which is the most common form of cardiac arrhythmia, is associated with high

CADTH - Health Technology Assessment2015

266. Do you need to use heparin when initiating Coumadin therapy in a patient with atrial fibrillation?

Do you need to use heparin when initiating Coumadin therapy in a patient with atrial fibrillation? Do you need to use heparin when initiating Coumadin therapy in a patient with atrial fibrillation? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do you need to use heparin when initiating Coumadin therapy in a patient (...) with atrial fibrillation? View/ Open Date 2015-06 Format Metadata Abstract Do you need to use heparin when initiating Coumadin therapy in a patient with atrial fibrillation? Evidence-Based Answer: While the evidence is limited, current guidelines and biochemical studies suggest that it is probably not necessary to use heparin when initiating warfarin therapy in a patient with chronic stable atrial fibrillation (SOR: C, expert opinion and disease-oriented evidence). URI Part of Citation Evidence-based practice 18

Evidence Based Practice 2015

267. Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project

Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project 25994754 2015 07 22 2016 04 25 2015 07 22 1522-9645 36 28 2015 Jul 21 European heart journal Eur. Heart J. Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project. 1822-30 10.1093/eurheartj/ehv163 The CHA2DS2VASc score (...) is a clinical risk stratification tool which estimates the risk of stroke and thromboembolism in non-valvular atrial fibrillation (AF). We aimed to establish the value of this score for risk evaluation in patients with non-valvular AF and valvular heart disease. Among 8053 patients with non-valvular AF (ESC guidelines definition), patients were categorized into Group 1 (no valve disease, n = 6851; 85%) and Group 2 (valve disease with neither rheumatic mitral stenosis nor valve prothesis, n = 1202; 15

EvidenceUpdates2015

268. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. BACKGROUND: It is uncertain whether bridging anticoagulation is necessary for patients with atrial fibrillation who need an interruption in warfarin treatment for an elective operation or other elective invasive procedure. We hypothesized that forgoing bridging anticoagulation would be noninferior to bridging with low-molecular-weight heparin for the prevention of perioperative arterial thromboembolism and would (...) thromboembolism was 0.4% in the no-bridging group and 0.3% in the bridging group (risk difference, 0.1 percentage points; 95% confidence interval [CI], -0.6 to 0.8; P=0.01 for noninferiority). The incidence of major bleeding was 1.3% in the no-bridging group and 3.2% in the bridging group (relative risk, 0.41; 95% CI, 0.20 to 0.78; P=0.005 for superiority). CONCLUSIONS: In patients with atrial fibrillation who had warfarin treatment interrupted for an elective operation or other elective invasive procedure

NEJM2015

269. Effect of Early Direct Current Cardioversion on the Recurrence of Atrial Fibrillation in Patients With Persistent Atrial Fibrillation

Effect of Early Direct Current Cardioversion on the Recurrence of Atrial Fibrillation in Patients With Persistent Atrial Fibrillation 25972054 2015 06 19 2015 08 25 2015 06 19 1879-1913 116 2 2015 Jul 15 The American journal of cardiology Am. J. Cardiol. Effect of early direct current cardioversion on the recurrence of atrial fibrillation in patients with persistent atrial fibrillation. 225-9 10.1016/j.amjcard.2015.04.013 S0002-9149(15)01107-8 In patients with persistent atrial fibrillation (AF (...) ), the sinus rhythm (SR) can be restored by direct current cardioversion (DCC), although the recurrence of AF after successful DCC is common. We examined whether transesophageal echocardiography (TEE)-guided early DCC, compared with the conventional approach of DCC after 3 weeks of anticoagulation with dabigatran-etexilat, reduces the recurrence of AF. A total of 126 consecutive patients with persistent AF were randomly assigned to a TEE followed by early DCC (n = 65) or to a conventional treatment

EvidenceUpdates2015

270. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation 25975659 2015 07 22 2016 04 25 2016 12 15 1522-9645 36 28 2015 Jul 21 European heart journal Eur. Heart J. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. 1805-11 10.1093/eurheartj/ehv177 VENTURE-AF is the first prospective randomized trial of uninterrupted rivaroxaban and vitamin K antagonists (...) (VKAs) in patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation (CA). Trial size was administratively set at 250, the protocol-specified target. Events were independently and blindly adjudicated. We randomly assigned 248 NVAF patients to uninterrupted rivaroxaban (20 mg once-daily) or to an uninterrupted VKA prior to CA and for 4 weeks afterwards. The primary endpoint was major bleeding events after CA. Secondary endpoints included thromboembolic events (composite

EvidenceUpdates2015

271. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study.

50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. BACKGROUND: Comprehensive long-term data on atrial fibrillation trends in men and women are scant. We aimed to provide such data through analysis of the Framingham cohort over 50 years. METHODS: We investigated trends in incidence, prevalence, and risk factors for atrial fibrillation and its association with stroke and mortality after onset in 9511 participants (...) enrolled in the Framingham Heart Study between 1958 and 2007. We analysed trends within 10 year groups (1958-67, 1968-77, 1978-87, 1988-97, and 1998-2007), stratified by sex. FINDINGS: During 50 years of observation (202,417 person-years), 1544 cases of new-onset atrial fibrillation occurred (of whom 723 [47%] were women). Between 1958-67 and 1998-2007, age-adjusted prevalence of atrial fibrillation quadrupled from 20·4 to 96·2 cases per 1000 person-years in men and from 13·7 to 49·4 cases per 1000

Lancet2015

272. Approaches to catheter ablation for persistent atrial fibrillation.

Approaches to catheter ablation for persistent atrial fibrillation. 25946280 2015 05 07 2015 05 13 2015 12 14 1533-4406 372 19 2015 May 07 The New England journal of medicine N. Engl. J. Med. Approaches to catheter ablation for persistent atrial fibrillation. 1812-22 10.1056/NEJMoa1408288 Catheter ablation is less successful for persistent atrial fibrillation than for paroxysmal atrial fibrillation. Guidelines suggest that adjuvant substrate modification in addition to pulmonary-vein isolation (...) is required in persistent atrial fibrillation. We randomly assigned 589 patients with persistent atrial fibrillation in a 1:4:4 ratio to ablation with pulmonary-vein isolation alone (67 patients), pulmonary-vein isolation plus ablation of electrograms showing complex fractionated activity (263 patients), or pulmonary-vein isolation plus additional linear ablation across the left atrial roof and mitral valve isthmus (259 patients). The duration of follow-up was 18 months. The primary end point was freedom

NEJM2015

273. Surgical ablation of atrial fibrillation during mitral-valve surgery.

Surgical ablation of atrial fibrillation during mitral-valve surgery. BACKGROUND: Among patients undergoing mitral-valve surgery, 30 to 50% present with atrial fibrillation, which is associated with reduced survival and increased risk of stroke. Surgical ablation of atrial fibrillation has been widely adopted, but evidence regarding its safety and effectiveness is limited. METHODS: We randomly assigned 260 patients with persistent or long-standing persistent atrial fibrillation who required (...) mitral-valve surgery to undergo either surgical ablation (ablation group) or no ablation (control group) during the mitral-valve operation. Patients in the ablation group underwent further randomization to pulmonary-vein isolation or a biatrial maze procedure. All patients underwent closure of the left atrial appendage. The primary end point was freedom from atrial fibrillation at both 6 months and 12 months (as assessed by means of 3-day Holter monitoring). RESULTS: More patients in the ablation

NEJM2015

274. Heart rate is associated with progression of atrial fibrillation, independent of rhythm

Heart rate is associated with progression of atrial fibrillation, independent of rhythm 25732748 2015 05 13 2015 07 20 2015 10 28 1468-201X 101 11 2015 Jun Heart (British Cardiac Society) Heart Heart rate is associated with progression of atrial fibrillation, independent of rhythm. 894-9 10.1136/heartjnl-2014-307043 Atrial fibrillation (AF) often progresses from paroxysmal or persistent to more sustained forms, but the rate and predictors of AF progression in clinical practice are not well (...) described. Using the Outcomes Registry for Better Informed Treatment of AF, we analysed the incidence and predictors of progression and tested the discrimination and calibration of the HATCH (hypertension, age, TIA/stroke, chronic obstructive pulmonary disease, heart failure) and CHA₂DS₂VASc scores for identifying AF progression. Among 6235 patients with paroxysmal or persistent AF at baseline, 1479 progressed, during follow-up (median 18 (IQR 12-24) months). These patients were older and had more

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

275. Leukoaraiosis and stroke recurrence risk in patients with and without atrial fibrillation

Leukoaraiosis and stroke recurrence risk in patients with and without atrial fibrillation 25695964 2015 03 24 2015 05 22 2015 03 24 1526-632X 84 12 2015 Mar 24 Neurology Neurology Leukoaraiosis and stroke recurrence risk in patients with and without atrial fibrillation. 1213-9 10.1212/WNL.0000000000001402 We aimed to investigate the association between leukoaraiosis and long-term risk of stroke recurrence adjusting for clinical scores developed and validated for the prediction of stroke risk (...) , such as CHADS2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and stroke or TIA) and CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or TIA, vascular disease, age 65-74 years, sex category). Study population was derived from the Athens Stroke Registry and was categorized in 2 subgroups according to the presence of atrial fibrillation (AF). Cox proportional hazards analysis was performed to assess the independent predictors of stroke

EvidenceUpdates2015

276. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs.

Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. In patients with non-valvular atrial fibrillation, oral anticoagulation with vitamin K antagonists reduces the risk of stroke by more than 60%. But vitamin K antagonists have limitations, including causing serious bleeding such as intracranial haemorrhage and the need for anticoagulation monitoring. In part related to these limitations, they are used in only about half (...) of patients who should be treated according to guideline recommendations. In the past decade, oral agents have been developed that directly block the activity of thrombin (factor IIa), as well as drugs that directly inhibit activated factor X (Xa), which is the first protein in the final common pathway to the activation of thrombin. These novel non-vitamin K antagonist oral anticoagulants (NOACs) have been shown to be at least as good as warfarin for stroke prevention in atrial fibrillation and they have

Lancet2015

277. Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial.

Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. 25467562 2015 03 10 2015 03 25 2015 06 16 1474-547X 385 9970 2015 Feb 28 Lancet (London, England) Lancet Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. 775-84 10.1016/S0140-6736(14)61992-9 (...) S0140-6736(14)61992-9 Patients are increasingly being admitted with chronic atrial fibrillation, and disease-specific management might reduce recurrent admissions and prolong survival. However, evidence is scant to support the application of this therapeutic approach. We aimed to assess SAFETY--a management strategy that is specific to atrial fibrillation. We did a pragmatic, multicentre, randomised controlled trial in patients admitted with chronic, non-valvular atrial fibrillation (but not heart

Lancet2015

278. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in BACKGROUND: Digoxin is a widely used drug for ventricular rate control in patients with atrial fibrillation (AF), despite a scarcity of randomised trial data. We studied the use and outcomes of digoxin in patients in the Rivaroxaban Once Daily (...) Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). METHODS: For this retrospective analysis, we included and classified patients from ROCKET AF on the basis of digoxin use at baseline and during the study. Patients in ROCKET AF were recruited from 45 countries and had AF and risk factors putting them at moderate-to-high risk of stroke, with or without heart failure. We used Cox proportional hazards

Lancet2015

280. Should Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) Receive Oral Anticoagulation?

Should Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) Receive Oral Anticoagulation? 25677422 2015 02 14 2015 04 06 2015 02 14 1558-3597 65 7 2015 Feb 24 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? 635-42 10.1016/j.jacc.2014.11.046 S0735-1097(14)07391-4 Although the CHA2DS2-VASc (...) (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, age 65 to 74 years, female) score is recommended by both American and European guidelines for stroke risk stratification in atrial fibrillation (AF), the treatment recommendations for a CHA2DS2-VASc score of 1 are less clear. This study aimed to investigate the risk of ischemic stroke in patients with a single additional stroke risk factor (i.e., CHA2DS2-VASc

EvidenceUpdates2015